CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 260 target
Drug / intervention
Celecoxibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00292721
NCT00292721Phase 4Completed
CompareCT.gov

Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial

Seoul National University Hospital·interventional·Posted Feb 16, 2006·Updated Jul 21, 2011

In Brief

A Phase 4 clinical trial evaluating Celecoxib for Coronary Arteriosclerosis. Completed, enrolled 260 participants across 1 site.

Detailed Summary

Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Arteriosclerosis
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 16, 2006
Enrollment StartAug 1, 2004
Primary CompletionOct 1, 2008
TodayJul 1, 2026
Enrollment to primary: 4.2 yearsPosted 20.4 years ago

Interventions

Celecoxibdrug

celecoxib: loading and maintenance for 6 months